OREANDA-NEWS  The main beneficiaries of the Russian pharmaceutical market may be companies from Asia, in particular from India, against the background of a decrease in the activity of Western players. Kommersant writes about this, referring to the DRT study (formerly Deloitte).

"DRT clients among Indian pharmaceutical companies have already shown interest in expanding their presence in Russia. India has long developed not only the production of ready-made dosage forms, but also substances. In addition, Indian generic manufacturers receive licenses from Western companies on better terms than Russian ones, which allows them to sell drugs at lower prices," said DRT partner Oleg Berezin.

Market participants indicated that the specifics of drug supplies in 2022 have not changed significantly, so there is no shortage on the market. In general, small local difficulties with deliveries can be observed periodically, but this does not affect the overall performance. In addition, some market participants noticed that so far the shares of Asian and local manufacturers in the number of packages sold have not changed.

Analysts added that Indian pharmaceutical companies occupied a significant share of the Russian market in the 90s, but eventually lost to Western companies, as well as local manufacturers. Now companies from India are in a better position, because due to sanctions they can supply products to the Russian market through other countries at higher prices. At the same time, the Russian pharmaceutical market continues to follow the path of import substitution, increasing its production capacity.